Erythropoietin Drugs Market Size On Position To Reach $11.9 Billion By 2027
Pune, Maharashtra, India, February 19 2021 (Wiredrelease) Allied Analytics –:Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and 70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.
According to a new report published by Allied Market Research, titled, “Erythropoietin Drugs Market by Product Types (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa) and Applications (Anemia, Kidney Disorders, Neural Disease and Wound healing) – Global Opportunity Analysis and Industry Forecast, 2020 – 2027″. Global Erythropoietin Drugs Market is expected to garner $11.9 billion by 2027, registering CAGR of 9.7% during the forecast period 2020 – 2027.
Download Report Sample PDF @ https://www.alliedmarketresearch.com/request-sample/59
Globally, ~70% of the market share is held by the developed regions owing to favorable reimbursements leading to affordability for EPO drugs. Going forward, owing to commercialization of EPO biosimilars, the Asia-Pacific EPO drugs market would be the most potential market among other regions.
Key findings of the study:
Europe led the global EPO drug market in 2013 closely followed by North AmericaAsia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies.
Currently, Anemia therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020.
Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/59
EPO drugs market is witnessing high commercialization of biosimilars for the ‘off-patent’ drug namely Erythropoietin alfa.
The first EPO drug – Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of biosimilar Erythropoietin alfa have been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals. In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for launch of Darbepoetin Alfa biosimilars. Some of leading players operating in EPO drug market are Amgen Inc., Johnson & Johnson, Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
To view the report, visit the website at http://www.alliedmarketresearch.com/erythropoietin-market
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.